Allurion TechnologiesALUR
ALUR
About: Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 24
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
4.2% more ownership
Funds ownership: 21.7% [Q2] → 25.9% (+4.2%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1% less capital invested
Capital invested by funds: $10.3M [Q2] → $10.2M (-$110K) [Q3]
16% less funds holding
Funds holding: 32 [Q2] → 27 (-5) [Q3]
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
475%
upside
Avg. target
$2
475%
upside
High target
$2
475%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
TD Cowen Joshua Jennings 42% 1-year accuracy 8 / 19 met price target | 475%upside $2 | Buy Initiated | 2 Oct 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the “Minimum Market Capitalization Standard”.
Neutral
Business Wire
3 weeks ago
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company's AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the.
Neutral
Seeking Alpha
1 month ago
Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executive Officer Brian Conyer – Vice President-Digital Health Adrian Wild – Senior Vice President-International Commercial Chris Geberth – Chief Financial Officer Conference Call Participants Josh Jennings – TD Cowen Matt Taylor – Jefferies Operator Thank you for standing by. My name is John, and I'll be your conference operator today.
Neutral
Business Wire
1 month ago
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% v.
Neutral
Business Wire
1 month ago
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion's largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual.
Neutral
Business Wire
1 month ago
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (int.
Negative
Zacks Investment Research
1 month ago
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.
Neutral
Business Wire
1 month ago
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year. "These submissions are a critical milestone for Allurion, and I commend ou.
Positive
Benzinga
2 months ago
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.
Neutral
Business Wire
2 months ago
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition. The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (BMI) of 31.3. After four months of balloon therapy, patients achieved an average weight reduction of 15.7%. Patients con.
Charts implemented using Lightweight Charts™